Axol Bioscience acquisition news – UK-based Axol Bioscience Ltd Acquired Phenocell SAS

The acquisition extends Axol’s portfolio of iPSC-derived cell models, adding skin and human retinal iPSC-derived cell lines to its existing neuroscience, pain and touch, and cardiovascular products and services.

Read also - Harmonic Security funding news – London-based Harmonic Security Raises $17.5Million in Series A Round Funding

Phenocell’s offering includes market-leading human iPSC-derived sebocytes and retinal pigment epithelium (RPE) and photoreceptor cells. Additionally, the company provides custom, skin and dry age-related macular degeneration (AMD) services to support drug discovery companies.

Liam Taylor, CEO, Axol Bioscience, said: “Axol has previously operated in three areas of drug research and discovery: neuroscience, pain and touch, and cardiovascular drug discovery. This acquisition enables us to extend our product portfolio into ophthalmology and dermatology and offer iPSC-based skin and vision loss models. We are delighted to welcome Phenocell to the Axol Bioscience family and look forward to building an even wider range of advanced in vitro models of human disease, combining our shared values and passion to accelerate drug discovery.”

Brigitte Onteniente, CEO and founder of Phenocell said, “We have built a unique set of products and services over the last decade to meet the growing requirements from the drug discovery and cosmetic industries to move from primary models to more consistent, human iPSC-derived models, As part of Axol Bioscience we look forward to working with Liam and the team to develop a larger range of models, to serve a wider market.”

About Phenocell

Phenocell is a research-based biotechnology company specialized in the creation, production, and commercialization of cellular models & bioassays for research and drug discovery. They are your designated partner for open innovation projects.

About Axol Bioscience

Axol Bioscience, they support your pursuit of more effective, safer therapies. Like you, they believe that having more human-relevant disease models which will expand your scientific knowledge and de-risk drug development. They use human iPSCs to achieve this and have been doing this since 2006.